Objective: The study objective was to investigate the prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression on tumor cells in early-stage adenocarcinoma of the lung, because both programmed death-ligand 1 and human leukocyte antigen class I molecules play important roles in cancer immunity.
Perspective
The prognostic impact of PD-L1 expression on tumor cells was distinct according to HLA class I expression status in pathologic stage I adenocarcinoma of the lung. Tumor cells with reduced HLA class I expression may evade immune attack to survive regardless of PD-L1 status. In contrast, tumor cells with normal HLA class I expression may evade immune attack when they express PD-L1.
See Editorial Commentary page 393.
See Editorial page 363.
Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer, which is the leading cause of cancer-related deaths worldwide. 1 For patients with early-stage NSCLC, surgery is the optimal treatment for cure. 2 However, the postoperative prognosis remains poor, and current adjuvant chemotherapy provides only a modest survival benefit. 3, 4 To improve the prognosis, it is important to establish novel biomarkers to predict prognosis and response to adjuvant chemotherapy. 4 The programmed-cell death 1 (PD-1) and its ligand (PD-L1) are emerging therapeutic targets in a variety of malignant tumors, including NSCLC. Tumor cells that express PD-L1 may survive immune regulation by binding to PD-1 on cytotoxic T cells (CTLs) and thereby downregulating CTL function, which otherwise would have attacked and killed the tumor cells. 5 Accordingly, blockade of the PD-1/PD-L1 axis may lead to killing tumor cells by restoring cancer immunity, and several antibodies against PD-1 or PD-L1 have achieved promising anti-tumor activity for advanced NSCLC. [6] [7] [8] [9] [10] More important, PD-L1 expression status on tumor cells has been established as a useful biomarker to predict anti-tumor activity of these therapeutic agents. [6] [7] [8] [9] In contrast, the prognostic impact of PD-L1 expression status in early-stage NSCLC remains unclear, partly because of heterogeneity in the patient population (eg, heterogeneous stage and histology) included in each study. 11 In addition, its prognostic impact may be affected by the status of other biological factors involved in cancer immunity, such as human leukocyte antigen (HLA) class I molecules that play critical roles in an earlier phase for recognition of tumor cells by CTLs. [12] [13] [14] Accordingly, tumor cells with reduced HLA class I molecules may evade immune attack to survive regardless of PD-L1 expression status, which can be associated with a poor prognosis. In contrast, tumor cells with normal HLA class I expression may be recognized and killed by CTLs without PD-L1 expression, and may evade immune attack only when they express PD-L1. However, only a few clinical studies, 1 on cholangiocarcinoma 15 and 1 on hepatocellular carcinoma, 16 have assessed the prognostic impact of PD-L1 expression status in combination with HLA class I status. To assess the prognostic impact of PD-L1 expression status in correlation with HLA class I expression status in NSCLC, we conducted a retrospective study in a homogenous patient population with completely resected pathologic (p-) stage I lung adenocarcinoma.
PATIENTS AND METHODS Patients
Patients with p-stage I lung adenocarcinoma who received complete resection at our institute (Second Department of Surgery [Chest Surgery], University of Occupational and Environmental Health, Japan) from January 2003 to December 2006 without induction therapy before surgery were retrospectively reviewed. All patients received lung resection through minimally invasive thoracotomy. Systemic nodal dissection was principally performed, but was actually performed in 83 patients. Nodal sampling was performed in 8 patients (3 aged 80 years, 3 with pulmonary comorbidities, and 2 with cardiovascular comorbidities). No nodal sampling was performed in 3 patients (2 patients with pulmonary comorbidities and 1 patient with immunosuppressive treatment for rheumatoid arthritis). In 5 patients who were not fit for lobectomy, limited surgery was performed as follows: segmentectomy in 2 patients (1 aged 80 years, 1 with severe chronic obstructive pulmonary disease) and wedge resection in 3 patients (2 with cardiovascular comorbidities and 1 with idiopathic pulmonary fibrosis) ( Table 1) .
Patients who did not provide written informed consent for this study were excluded. Patients were ineligible if adequate primary tumor samples for immunohistochemistry (IHC) were not available, and a total of 94 patients were finally included in the study (Figure 1 ). Whole-body computed tomography, brain magnetic resonance imaging, and bone scan were performed preoperatively. P-stage was determined according to the TNM classification (Union for International Cancer Control TNM staging system, 7th edition). Patients with p-stage IB disease who were fit for adjuvant chemotherapy were encouraged to participate in clinical trials, and 10 patients actually received adjuvant chemotherapy ( Table 1) . The institutional review board of the University of Occupational and Environmental Health, Japan, approved the present study.
Follow-up Protocol
For each patient, a routine follow-up was performed at the outpatient clinic as follows: chest roentgenography every 3 months, as well as chest computed tomography, brain magnetic resonance imaging, and bone scan every 6 months for the first 3 years after surgery; all examinations were performed annually thereafter. Additional examinations were performed when any symptoms or signs of recurrence were detected.
The overall survival (OS) was estimated from the date of surgery to death of any cause or the date of the last follow-up. Patients who were not confirmed dead were censored on the date of the last follow-up. A telephone follow-up would be made if the patient did not come to our clinic for a routine follow-up.
Immunohistochemistry
Serial 4-mm sections were cut from each formalin-fixed and paraffin-embedded primary tumor specimen, and received hematoxylineosin staining and IHC staining as described previously. 16 Sections were heated in 1 mmol/L ethylenediaminetetraacetic acid (pH 8.0) at 98 C for 15 minutes for antigen retrieval and incubated in 3% hydrogen peroxide for 10 minutes to inactivate endogenous peroxidase. After blocking with Protein Block Serum-Free (Agilent Technologies, Carpinteria, Calif) for 30 minutes, sections were incubated with rabbit anti-PD-L1 monoclonal antibody (clone E1L3N, Cell Signaling Technology Japan, Tokyo, Japan) diluted at 1:200 for 1 hour at room temperature. Sections were then washed and incubated with SignalStain Boost IHC Detection Reagent HRP Rabbit (Cell Signaling Technology Japan) for 30 minutes. Thereafter, they were visualized with DABþ Liquid (Agilent Technologies) and counterstained with hematoxylin.
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Each slide was independently examined by 2 of the investigators (A.H. and S.S.) without any knowledge of the clinical data. When a discrepancy was found between the 2 investigators, a consensus was reached via their simultaneous examination using a double-headed microscope. Each tumor cell was judged as positive staining for PD-L1 when the membrane was stained at any intensity. Each patient was classified into ''negative'' PD-L1 or ''positive'' PD-L1 according to the percentage of PD-L1-positive tumor cells; 3 exploratory cutoff values (1%, 5%, 50%), which were identified in previous clinical studies, [6] [7] [8] [9] [10] [11] were used and analyzed. HLA class I expression had been evaluated in a previous study with IHC using an anti-HLA class I antibody (EMR8-5, Cosmo Bio, Tokyo, Japan). Data represented as absolute counts (%) or median (range). PD-L1, Programmed death-ligand 1; HLA, human leukocyte antigen; EGFR, epidermal growth factor receptor.
Statistical Analyses
The proportions of categoric data were compared by the chi-square test. Continuous data were compared using a nonparametric test (Mann-Whitney U test).
The Kaplan-Meier method was used to estimate the probability of survival, and survival differences were analyzed by the log-rank test. To identify independent prognostic factors, univariable and multivariable analyses using Cox proportional hazards regression models were performed. Variables with a P value less than .1 in the first univariable analyses were included in multivariable models. The hazard ratio (HR) and 95% confidence interval (CI) were calculated for each variable.
All statistical analyses were performed with EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a modified version of R (The R Foundation for Statistical Computing, Vienna, Austria). 17 
RESULTS

Programmed Death-Ligand 1 Expression in Lung Adenocarcinoma
PD-L1 expression was positive in 21 patients (22.3%) at the cutoff value of 1%, 15 patients (16.0%) at the cutoff value of 5%, and 5 patients (5.3%) at the cutoff value of 50%.
Positive PD-L1 expression was more frequently seen in poorly differentiated tumors than in well-differentiated tumors. In addition, positive PD-L1 expression seemed to be less frequent among epidermal growth factor receptor-mutated tumors. No significant correlation between PD-L1 expression status at any cutoff value and smoking status was observed (Table 1) .
In this cohort, HLA class I expression was ''normal'' in 54 patients (57%) and ''reduced'' in 40 patients (43%).
No significant correlation was observed between HLA class I expression and PD-L1 expression, and no other patient characteristic was observed (Table 1) .
Programmed Death-Ligand 1 Expression and Survival
The median follow-up period for all patients was 61.2 months. The 5-year OS of PD-L1-positive and PD-L1-negative patients using each cutoff value was 76.2% and 85.1% (cutoff, 1%; P ¼ .249) (Figure 2, A) , 66.7% and 85.9% (cutoff, 5%; P ¼ .049) (Figure 2, B) , and 40.0% and 85.3% (cutoff, 50%; P ¼ .005) (Figure 2, C) , respectively, showing that positive PD-L1 expression with higher cutoff values was associated with a poor prognosis.
There was no significant difference in OS according to HLA class I status (5-year survival, 79.1% in ''reduced'' patients vs 85.3% in ''normal'' patients; P ¼ .378). An additional exploratory analysis in which the percentage of tumor cells expressing HLA class I was used as a continuous variable also revealed no significant correlation between HLA class I expression status and OS (HR, 0.999; 95% CI, 0981-1.017; P ¼ .891).
When analyzed by PD-L1 expression status with stratification by HLA class I status, a significantly poor prognosis in PD-L1-positive patients (cutoff value, 5% or 50%) was documented only when HLA class I expression was ''normal'' (Video 1). The 5-year survivals of PD-L1-negative and positive patients were 88.6% versus 76.9% at the cutoff value of 1% (P ¼ .186); 89.4% versus 62.5% at the cutoff value of 5% (P ¼ .029) ( Figure 3, A) ; and 88.3% versus 50.0% at the cutoff value of 50% (P ¼ .022) (Figure 3, C) , respectively. PD-L1 expression (cutoff value, 5%) along with sex and p-stage were included in a multivariable analysis (model 1), and PD-L1 positivity was a marginal factor to predict a poor prognosis (HR, 3.099; 95% CI, 0.956-9.261; P ¼ .058) ( Table 2) . In a multivariable analysis in which PD-L1 expression (cutoff value, 50%) was included (Model 2), the prognostic impact of PD-L1 positivity seemed less significant (HR, 4.372; 95% CI, 0.804-13.771; P ¼ .088) ( Table 2) . Among patients with ''reduced'' HLA class I expression, PD-L1 expression status provided no prognostic impact: 5-year survival, 80.4% versus 75.0% at the cutoff value of 1%; 80.9% versus 71.4% at the cutoff value of 5% 
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Hirai et al ( Figure 3, B) ; 81.4% versus 0.0% at the cutoff value of 50% (Figure 3, D) . Analyses among patients who did not receive adjuvant chemotherapy provided similar results (Table E1) .
DISCUSSION
In the present study, we first showed that positive PD-L1 expression status on tumor cells was a potential factor to predict a poor prognosis, which may depend on concurrent HLA class I expression status on tumor cells in lung adenocarcinoma. PD-L1 positivity was found to be correlated with a poor prognosis when concurrent HLA class I was adequately expressed on tumor cells, but PD-L1 expression status provided no prognostic impact when concurrent HLA class I expression was reduced.
The clinical implications of PD-L1 expression status in NSCLC have been reported in previous studies, 11 in correlation with tumor characteristics including mutational burden, prognosis, and response to immune-checkpoint inhibitors, such as anti-PD-1 antibodies (ie, nivolumab 6,7 and pembrolizumab 8 ) and anti-PD-L1 antibodies (ie, atezolizumab 9 and durvalumab 10 ). In many studies conducted for advanced NSCLC, positive or stronger PD-L1 expression was correlated with favorable clinical benefits achieved with anti-PD-1/PD-L1 antibodies. [7] [8] [9] As for the prognostic impact of PD-L1, however, many conflicting results have been reported, partly because of the vast heterogeneity of patient characteristics, including histologic subtypes and tumor stage, indicating the need for studies with homogenous patient populations. Accordingly, in the current study, we assessed the prognostic impact exclusively among patients with completely resected p-stage I lung adenocarcinoma. When we systematically searched for similar articles in PubMed as of December 31, 2016, using the terms ''lung'' and ''adenocarcinoma'' and ''PD-L1'' and ''survival OR prognosis'' only in the English literature, 13 eligible articles were identified [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] (Table 3) . Ten of 23 searched articles were ineligible, because no prognostic impact of PD-L1 expression status was examined. Most studies (9 of 13 searched studies, along with the present study) indicated a significantly poor prognosis in positive PD-L1 patients, whereas 3 studies indicated a favorable prognosis in positive PD-L1 patients. 18, 25, 27 Concerning clinicopathologic and molecular features, most studies showed that positive PD-L1 expression was associated with increased smoking history and poor differentiation, and the significant association between PD-L1 expression and poor differentiation also was documented in the current study. Five studies showed a positive association between the PD-L1 expression and the absence of epidermal growth factor receptor mutations, as a similar trend shown in the present study. In contrast, 1 study showed a positive association between the PD-L1 expression and the presence of epidermal growth factor receptor mutations. 20 Overall, positive PD-L1 expression was associated with more aggressive tumor behavior such as poor differentiation in adenocarcinoma of the lung, but the prognostic impact may remain controversial in such a homogenous population. Therefore, the prognostic impact of PD-L1 expression may be influenced by other factors associated with cancer immunity, such as HLA class I.
Cancer immunity comprises a series of steps as follows: (1) tumor cells with HLA class I expression can be recognized by CTLs and may evade immune attack by expressing PD-L1, which also may account for the result that PD-L1 positivity was associated with a poor prognosis in tumors with normal HLA class I expression. In the present study, a multivariate analysis failed to show a significant FIGURE 3 . OS according to PD-L1 expression status after stratification by HLA class I expression status. HLA class I status was classified on the basis of the percentage of tumor cells expressing HLA class I molecules into ''normal'' (80%) or ''reduced'' (<80%). A, OS curves of PD-L1 5% or greater and less than 5% cases among ''normal'' HLA class I cases. B, OS curves of PD-L1 5% or greater and less than 5% cases among ''reduced'' HLA class I cases. C, OS curves of PD-L1 50% or greater and less than 50% cases among ''normal'' HLA class I cases. D, OS curves of PD-L1 50% or greater and less than 50% cases among ''reduced'' HLA class I cases. CI, Confidence interval; PD-L1, programmed death-ligand 1. HLA, Human leukocyte antigen; HR, hazard ratio; CI, confidence interval; EGFR, epidermal growth factor receptor; PD-L1, programmed death-ligand 1.
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prognostic value of PD-L1 expression in tumor with normal HLA class I expression (P ¼ .058), most likely because of a relatively small number of patients.
Study Limitations
Although this study suggested that the prognostic values of PD-L1 expression were distinct according to HLA class I expression, this study had several limitations due to a variety of weaknesses other than its small number of patients. First, this study was a retrospective single-institutional study. Second, a certain percentage of patients were lost to follow-up in this study (approximately one fourth of patients at 5 years after surgery). In addition, the impact of PD-L1 status on postoperative recurrence and postoperative death is important, which was not examined in this study because adequate recurrence data were not available. Finally, the number of events for OS analysis was relatively small (15 deaths in the entire study cohort). To draw more conclusive results, we are currently conducting a larger-scale retrospective study. In addition, the prognostic impact of PD-L1 may be influenced not only by HLA class I but also by other factors associated with immune response (eg, major histocompatibility complex class II molecules and PD-1) and other pathologic factors (eg, specific subtypes of adenocarcinoma), and these factors should be included and analyzed in future studies. 
CONCLUSIONS
The prognostic impact of PD-L1 expression was distinct according to HLA class I expression status in resectable adenocarcinoma of the lung. PD-L1 positivity on tumor cells was associated with a poor prognosis when HLA class I expression was normal, but was not associated with prognosis when HLA class I expression was reduced.
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